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Abstract
Background: We assessed the expression of cytokeratin (CK) and apomucin (MUC) in ampullary carcinoma (AC) to
develop a system for the classification of ACs on the basis of their clinical significance.
Method: We studied the expressions of CK7, CK20, MUC1, MUC2, MUC5AC, and MUC6 in 43 patients with ACs.
Clinical data were obtained retrospectively by examining surgically resected ACs of the patients.
Results: We classified the cases into 3 groups: tumors expressing CK20 and lacking MUC1 (intestinal type [I-type],
26%), tumors expressing MUC1 and lacking CK20 (pancreatobiliary type [PB-type], 35%), and those expressing or
lacking both CK20 and MUC1 (other type [O-type], 39%). Eight (73%) of 11 I-type carcinomas, 3 (20%) of 15 PB-type
carcinomas, and 4 (24%) of 17 O-type carcinomas were classified as pT1. The number of I-type carcinomas in the
early tumor stages was significantly higher than the number of PB- and O-type carcinomas (p = 0.014 and p =
0.018, respectively). The 5-year survival rates for pT1, pT2, and pT3 tumors were 76%, 33%, and 22%, respectively
(p < 0.001). Rates of MUC5AC and MUC6 coexpression for I-type, PB-type, and O-type tumors were 18%, 13%, and
53%, respectively. There was a significant correlation between MUC5AC and MUC6 coexpression and O-type
characteristics (p = 0.031). The five-year survival rates for O-type ACs with and without MUC5AC and MUC6
coexpression were 71% and 17%, respectively (p = 0.048).
Conclusions: The immunohistochemical subtypes based on CK and MUC expression correlated with tumor
progression. Gastric MUC5AC and MUC6 coexpression correlated with better prognosis for O-type ACs.
Background
Ampullary carcinomas (ACs), although uncommon, have
a better prognosis than other periampullary tumors such
as pancreatic and bile duct carcinomas.
The ampulla of Vater consists of 4 minor anatomic
regions: the ampulloduodenum (Ad), the ampullopan-
creatobiliary common duct (Ac), the ampullopancreatic
duct (Ap), and the ampullobiliary duct (Ab)[1,2]. The
ampulla is formed by the union of 2 distinct types of
mucosa. The Ad is covered by intestinal mucosa, while
the other parts of the ampulla of Vater (the Ap, Ab, and
Ac) are lined with pancreatobiliary-type ductal mucosa
[2,3]. Therefore, ACs may arise from the intestinal-type
mucosa as well as from the pancreatobiliary-type mucosa;
this may explain the broad histomorphologic spectrum of
these tumors[1]. Tumor progression and prognosis are
affected by the primary AC tumor sites [1,3,4].
Kimura et al. classified ACs into 2 histological subtypes:
intestinal and pancreatobiliary[3]. Albores-Saavedra et al.
further defined the characteristics of these 2 types and
also described unusual types such as signet-ring cell car-
cinoma and undifferentiated carcinoma[4].
While histopathological typing is a useful method for
classifying ACs, some cases cannot be easily classified by
using histomorphology[1]. Determination of the cytoker-
atin (CK) and apomucin (MUC) immunophenotypes of
an AC can facilitate identification of the primary tumor
site[1,2,5-7]. Most pancreatobiliary adenocarcinomas
express CK7 and low levels of CK20[6,8,9]. Among ACs,
the pancreatobiliary type expresses CK7 but does not
express CK20, while the intestinal type expresses CK20
but does not express CK7[5].
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MUC1 but do not express MUC2[6,7,9,10]. Most intest-
inal-type ACs express MUC2[1,2,5,6].
In the present study, we analyzed the spectrum of CK
and MUC expression in 43 patients with ACs. We then
evaluated the immunohistochemical subtypes of ACs by
analyzing the expressions of CK7, CK20, MUC1, MUC2,
MUC5AC, and MUC6 in these tumors. Further, we
assessed the correlations between the histomorphologi-
cal findings and the defined immunohistochemical sub-
types and evaluated the clinical significance of these
immunohistochemical AC subtypes; the classification of
ACs on the basis of their immunohistochemical charac-
teristics may be useful to predict the clinical outcome.
Materials and methods
Clinical data were obtained retrospectively from ACs
that were surgically resected from 43 patients (22 men
and 21 women) with an average age of 66.4 years
(range, 44-82 years). All resected specimens had been
obtained between 1983 and 2007 and were maintained
at the Department of Digestive and General Surgery,
Faculty of Medicine, Shimane University. All but 5
patients underwent pancreatoduodenectomy. The other
5 underwent pancreas-sparing duodenectomy. All
tumors included in this study histologically showed sur-
gically negative margins.
The study was approved by the hospital’se t h i c sc o m -
mittee. Informed consent was obtained from all patients
for the subsequent use of resected tissues.
Histopathological examinations were performed
according to the guidelines of the Japanese Society of
Biliary Surgery[11]. The Tumor, Node, Metastasis
(TNM) Staging System put forth by the International
Union Against Cancer was used for tumor classification
[12]. All tumors were classified histologically according
to the criteria published by Albores-Saavedra et al[4].
Intestinal-type carcinomas are composed of well-formed
tubular to elongated glands, complex cribriform areas,
and solid nests indistinguishable from those found in
colorectal adenocarcinoma, whereas pancreatobiliary-
type carcinomas mostly consist of simple or branching
glands and small solid nests of cells surrounded by a
strikingly desmoplastic stroma (Figure 1). Mixed-pattern
tumors were classified into the intestinal- or pancreato-
biliary-type groups on the basis of their predominant
component. Carcinomas of the unusual types included
undifferentiated, mucinous, signet-ring cell, and solid
carcinomas.
Histological and Immunohistochemical Staining
All specimens were fixed in 4% buffered formaldehyde
and embedded in paraffin. The samples were sectioned
(section thickness, 3 μm) and stained with hematoxylin
and eosin. Subsequently, all tissue samples, including
carcinoma tissues, were stained immunohistochemically
with the following antibody panel: monoclonal antibo-
dies to cytokeratin 7 (CK7, OV-TL12/30, dilution 1:100;
D a k oC y t o m a t i o n ,C a r p i n t e r i a ,C A ) ,c y t o k e r a t i n2 0
(CK20, Ks20.8, dilution 1:50; Dako Cytomation), apomu-
cin MUC1 (clone Ma695, 1:100; Novocastra, Mount
Waverley, Australia), apomucin MUC2 (clone Ccp58,
1:100; Novocastra), apomucin MUC5AC (clone CLH2,
1:150; Novocastra), and apomucin MUC6 (clone CLH5,
1:150; Novocastra).
Immunohistochemical staining was performed on an
immunostainer (Benchmark XT; Ventana Medical Sys-
tem, Tucson, AZ) with the use of an amplification kit
(Ventana). Antibody detection was performed by adding
biotinylated secondary antibodies, avidin-biotin complex,
and 3,3’-diaminobenzidine.
The cytoplasmic and membranous immunoreactivities
of CK7, CK20, MUC1, MUC2, MUC5AC, and MUC6
were assessed. Only those samples showing greater than
10% tumor-cell positivity were regarded as positive.
Statistical Analysis
Survival curves were calculated by the Kaplan-Meier
method and compared with the results of the log-rank
test. Agreement between the histological and immuno-
histochemical classifications was evaluated using the
-coefficient. A two-tailed Fisher’se x a c tt e s to rc
2 test
was used to compare the immunohistochemical classifi-
cation and clinicopathological parameters, as appropri-
ate. Probability (p) values of < 0.05 obtained by the two-
tailed test were regarded as statistically significant.
The JMP software program (ver. 5.0.1; SAS Institute
Inc, Cary, NC) was used for all statistical analyses.
Results
Patient Characteristics and Histological Classification
Fifteen (35%) of the 43 tumors were pT1, 11 (25%) were
pT2, and 17 (40%) were pT3. Twenty-two (51%) and 21
(49%) of the 43 tumors were negative and positive for
lymph node involvement, respectively.
In the assessment according to the histological criteria
proposed by Albores-Saavedra et al.,[4] we found 16
(37%) tumors to be intestinal-type carcinomas, 18 (42%)
to be pancreatobiliary-type carcinomas, and 9 (21%) to
be unusual-type carcinomas (Table 1).
Correlations between Histological Classification and
Immunohistochemical Parameters
The histological classification[4] indicated that CK20
had high sensitivity (100%) for intestinal-type carci-
n o m aa n dt h a tM U C 1h a dh i g hs e n s i t i v i t y( 9 4 % )f o r
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and both correlations were significant (p < 0.001 and
p < 0.001, respectively).
Immunohistochemical Classification of Tumors
We tried to further classify ACs into 3 subtypes on the
basis of the expression of CK20 and MUC1 in the
intestinal mucosa and the pancreatobiliary mucosa:
tumors expressing CK20 and lacking MUC1 were
defined as intestinal type (I-type); tumors expressing
MUC1 and lacking CK20 were defined as pancreatobili-
ary type (PB-type); and carcinomas expressing or lacking
both CK20 and MUC1 were defined as other type (O-
type). Eleven (26%) of the 43 tumors were I-type, 15
(35%) were PB-type, and 17 (39%) were O-type.
Correlation Analysis of Histological and
Immunohistochemical Classifications
Ten of the 16 carcinomas of the histological intestinal
type were of the immunohistochemical I-type, but none
was of the immunohistochemical PB-type. Thirteen of
the 18 carcinomas of the histological pancreatobiliary
type were of the immunohistochemical PB-type, while
none was of the immunohistochemical I-type (Table 3).
T h es e n s i t i v i t yo ft h em a r k e rf o rt h ec o e x p r e s s i o no f
CK20 and MUC1 for the histological intestinal type,
A B C
DEF
Figure 1 Expression of cytokeratin and apomucin for histological classification. Intestinal-type carcinomas are composed of well-formed
tubular to elongated glands and complex cribriform areas indistinguishable from colorectal adenocarcinomas (A), and they are
immunohistochemically stained by the CK20 antibody (B) but show no reaction to the MUC1 antibody (C). Pancreatobiliary-type carcinomas
mostly consist of simple or branching glands surrounded by strikingly desmoplastic stroma (D) negative for CK20 (E) and positive for MUC1
antibody (F) (A, D: hematoxylin and eosin stain, ×20; B, C, E: ×20;F ×50).
Table 1 Clinicopathological Data of 43 Ampullary
Carcinomas
Median age, years (range) 66.4 (44-82)
Gender
Male 22 51.0%
Female 21 49.0%
Histological classification*
Intestinal type 16 37.0%
Pancreatobiliary type 18 42.0%
Unusual type 9 21.0%
T stage
I 15 35.0%
II 11 25.5%
III 17 39.5%
IV 0 0.0%
Nodal metastasis
Negative 21 49.0%
Positive 22 51.0%
*according to reference [4].
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63%, 72%, and 67%, respectively, and the specificity
for these types were 96%, 92%, and 68%, respectively
(Table 4). Further, the immunohistochemical subtypes
defined in our study correlated well with the conven-
tional histological classification (-coefficient = 0.518;
p < 0.001).
Correlations between Immunohistochemical Classification
and Tumor Parameters
Eight (73%) of the 11 I-type tumors, 3 (20%) of the 15
PB-type tumors, and 4 (24%) of the 17 O-type tumors
were classified as pT1 according to the immunohisto-
chemical classification system. Lymph node metastasis
was observed in 3 (27%) of the 11 I-type ACs, 9 (60%)
of the 15 PB-type ACs, and 9 (53%) of the 17 O-type
ACs (Table 5). Thus, the immunohistochemical I-type
had significantly better pT stage than the immunohisto-
chemical PB-type and O-type tumors (Fisher’s exact
test, p = 0.014 and p = 0.018, respectively) (Table 6).
However, there were no significant differences in the
frequency of lymph node metastasis among the immu-
nohistochemical subtypes. (Fisher’se x a c tt e s t ,p=0 . 1 3 0
and p = 0.253, respectively)
Survival Analysis
The survival time of the 43 patients was 4.23 ± 0.64
years (mean ± SEM, Kaplan-Meier). The 5-year survival
rate for all AC cases was 41.2%. The 5-year survival
rates for pT1, pT2, and pT3 cases were 76%, 33%, and
22%, respectively (Figure 2). The 5-year survival rates
for node-negative and node-positive cases were 61% and
19%, respectively (Figure 3). There was a significant dif-
ference in the cumulative survival between pT and N
cases (p < 0.001 and p < 0.001, respectively). The 5-year
survival rates for the histological intestinal, pancreato-
biliary, and unusual types were 62%, 33%, and 25%,
respectively (p = 0.034) (Figure 4). However, the 5-year
survival rates for the immunohistochemical I-type, PB-
type, and O-type were 55%, 35%, and 41%, respectively;
therefore, we concluded that there was no significant
correlation between survival and immunohistochemical
subtypes (p = 0.560) (Figure 5).
Relationships between MUC5AC and MUC6 Expression
and Immunohistochemical Subtypes
The rate of coexpression of MUC5AC and MUC6 in
tumors of the immunohistochemical I-type, PB-type, and
O-type were 18%, 13%, and 53%, respectively. Significant
correlations were noted between MUC5AC and MUC6
coexpression and immunohistochemical subtypes (p =
0.031) (Figure 6) (Table 7). For the immunohistochemical
O-type, the 5-year survival rates of patients with tumors
coexpressing MUC5AC and MUC6 and with those lack-
ing both antigens were 71% and 17%, respectively.
One (11%) of the 9 tumors positive for MUC5AC and
MUC6 coexpression and 4 (50%) of the 8 tumors
Table 3 Correlation between Immunohistochemical and
Histological Classifications
Immunohistochemical classification
I-type PB-type O-type
Histological classification
Intestinal type 10 0 6
Pancreatobiliary type 0 13 5
Unusual type 1 2 6
I-type: intestinal type; PB-type: pancreatobiliary type; O-type: other type.
Table 2 Immunohistochemical Expression by Histological Classification
Positive cases (%)
Intestinal type Pancreatobiliary type Unusual type P*
(N = 16) (N = 18) (N = 9)
CK7 13 (81) 17 (94) 9 (100) (p = 0.178)
CK20 16 (100) 4 (22) 6 (67) (p < 0.001)
MUC1 6 (38) 17 (94) 7 (78) (p < 0.001)
MUC2 4 (25) 2 (11) 2 (22) (p = 0.540)
MUC5AC 6 (38) 8 (44) 5 (56) (p = 0.683)
MUC6 7 (44) 5 (28) 5 (56) (p = 0.341)
* c
2 test. The percentage represents sensitivity.
Table 4 Sensitivity, Specificity, Positive Predictive Value,
and Negative Predictive Value of Combined Expression
of CK20 and MUC1 According to the Histological Type
Histological type Maker Sensitivity Specificity PPV NPV
Intestinal type
CK20
+MUC1
0.625 0.963 0.909 0.813
Pancreatobiliary
type
CK20
+MUC1
0.722 0.920 0.867 0.821
Unusual type
CK20
+MUC1
0.666 0.676 0.353 0.885
PPV, positive predictive value; NPV, negative predictive value.
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classified into stage pT3 (Table 8).
Among the patients with immunohistochemical O-
type tumors, those with tumors coexpressing MUC5AC
and MUC6 had significantly longer cumulative survival
than those with tumors that did not show this coexpres-
sion (p = 0.048) (Figure 7).
Discussion
Albores-Saavedra et al. defined 3 types of ACs–the
intestinal type, the pancreatobiliary type, and the unu-
sual type[4].
In the present study on ACs, we histologically classified
these tumors into these 3 types, and 37% were of the
intestinal type, 42% were of the pancreatobiliary type,
and 21% were of the unusual type[4]. According to the
histological criteria, Zhou et al. reported the rates of the
histological intestinal, pancreatobiliary, and unusual
types to be 27%, 44%, and 29%, respectively[5]. According
to their histological criteria, the unusual type included
mucinous, signet-ring cell, solid, or undifferentiated car-
cinomas[4,5]. However, Kimura et al. simply classified
ACs into 2 types, intestinal and pancreatobiliary[3].
Because these systems of histological classification use
different sets of criteria,[3,4] we tried to create a simple
AC classification system based on immunohistochemical
staining of CKs and MUCs. Goldstein et al. reported
positive CK7 expression in 100% and positive CK20
expression in 43% of ACs, but it was difficult to distin-
guish between pancreatic carcinomas and ACs by the
coordinate staining patterns of CK7 and CK20[9]. Very
few reports have examined the expression patterns of
CK and MUC in the AC subtypes[1,5,6].
In a previous study, the CK7+/CK20-/MUC2- pattern
in the histological intestinal-type carcinoma and the
CK7-/CK20+/MUC2+ pattern in the histological pan-
creatobiliary-type carcinoma indicated that these differ-
ent types of ACs had developed from 2 different types
of mucosa in the ampulla of Vater[1]. Chu et al.
reported positive expression of CK7, CK20, and MUC2
in the histological intestinal-type and positive expression
of CK7 and MUC1 in the histological pancreatobiliary-
type and that ACs of pancreatobiliary origin showed
immunophenotypes similar to that of pancreatic ductal
carcinoma[6]. Zhou et al. were the first to show agree-
ment between the histological classification and the
immunohistochemical characterization based on cyto-
keratins[5]. However, their immunohistochemical classi-
fication did not correlate with tumor progression and
prognosis.
Although most other studies have described immuno-
histochemical classification systems based on the expres-
sion of either MUC[2] or CK[5], we analyzed the
expression of both in ACs.
Table 5 Correlations of Tumor Parameters with Both Histological and Immunohistochemical Classifications
Histological type (No. of cases) Immunohistochemical type (No. of cases)
I-type PB-type U-type I-type PB-type O-type
(N16) (N = 18) (N = 9) (N = 11) (N = 15) (N = 17)
T-stage
I 1 0 4 1 834
I I 4 5 2 038
III 2 9 6 3 9 5
I V 0 0 0 000
Nodal metastasis
Negative 13 7 2 8 6 8
Positive 3 11 7 3 9 9
I-type, intestinal type; PB-type, pancreatobiliary type; U-type, unusual type; O-type, other type.
Table 6 Relationships between Tumor Groups and Tumor Parameters
Two-Tailed P*
Tumor parameters I-type vs. PB-type type PB-type vs. O-type I-type vs. O-type
Histological classification
T1 vs. T2/T3 0.017 0.483 0.013
N0 vs. N1 0.012 0.386 0.003
Immunohistochemical classification
T1 vs. T2/T3 0.014 0.809 0.018
N0 vs. N1 0.130 0.734 0.253
* Fisher’s exact test.
Other type implies histological unusual type.
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in the expression levels of the histological intestinal type
and the histological pancreatobiliary type, with the sen-
sitivity being 100% for CK20 and 94% for MUC1 expres-
sion, respectively. These results indicate that the CK20
+/MUC1- pattern fully corresponds to the immunohis-
tochemical I-type and that the CK20-/MUC1+ pattern
fully corresponds to the immunohistochemical PB-type.
With regard to immunohistochemical classification
systems, Zhou et al classified ACs on the basis of the
combined expression of CK7 and CK20, while Chu et al
classified ACs on the basis of the combined expression
of CDX2, CK17, MUC1, and MUC2.
Little is known, however, about the combined expres-
sion of CK20 and MUC1 in ACs. The possibility of
identifying the primary AC site is increased when the
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Figure 2 Cumulative survival of patients according to pathological tumor stage (pT). Patients with early-stage tumors (pT1) showed
significantly better survival than those with advanced-stage tumors (pT2 and pT3) (p < 0.001).
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Figure 3 Cumulative survival of patients with lymph node metastasis (N). Node-positive (N1) patients showed significantly poorer survival
than node-negative (N0) patients (p < 0.001).
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expression of either one of them, is taken into account.
We found that the classification of the immunohisto-
chemical subtypes based on the expression of both CK20
and MUC1 correlated well with histological typing
(-coefficient = 0.5184). Using this immunohistochemical
classification system based on the coordinated expression
of CK20 and MUC1, we were able to determined that
2 of 9 tumors classified as the histological unusual type
expressed the pancreatobiliary pattern in immunohisto-
chemical analysis, while 1 of these 9 tumors expressed
the intestinal pattern.
Previous studies have shown that the prognosis of AC
patients depends on the pT stage, nodal metastasis, and
histological type[1,4,13-17]. Similarly, our results indi-
cated that the pT stage, nodal metastasis, and histological
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Figure 4 Cumulative survival of patients with ACs of different histological types: intestinal-type, pancreatobiliary-type, and unusual-
type. Patients with intestinal-type tumors showed significantly better survival than those with the pancreatobiliary- and unusual-type tumors (p
= 0.031).
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Figure 5 Cumulative survival of patients based on immunohistochemical classification (I-type, PB-type, and O-type). There were no
differences among the 3 immunohistochemical subtypes in terms of cumulative survival of patients with AC (p = 0.56).
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According to our histological classification method, a
large number of intestinal type ACs were at stage pT1
(60%) and node-negative (81%). These results indicate
that progression of the intestinal-type tumor is slower
and the risks of nodal metastasis lower than those in the
case of the pancreatobiliary- and unusual-type tumors.
In our immunohistochemical classification, the pT
stage correlated significantly with the immunohisto-
chemical subtypes. Although the number of immunohis-
tochemical I-type tumors in the early pT stages was
significantly greater than the number of immunohisto-
chemical PB-type and O-type tumors in the same stages,
there were no significant differences in the cumulative
survival. This result may be attributable to the lack of
differences in the nodal metastasis risks associated with
the immunohistochemical I-type and PB-type. This may
indicate that the risks of nodal metastasis are similar
among the intestinal, pancreatobiliary, and other types.
Therefore, pancreatoduodenectomy with lymph node
dissection should be performed for adequate surgical
resection in AC[18]. If function-preserving surgery has
been selected for AC, the histological classification sys-
tem is currently more useful than our immunohisto-
chemical classification method.
Gürbüz et al. reported that MUC5AC- and MUC6-
positive expression patterns were regarded as represent-
ing gastric differentiation and that negative expression
of both indicated the intestinal type of AC[7]. Zhou
et al. showed that gastric MUC5AC expression corre-
lated well with PB-type carcinomas[5]. Interestingly, we
found that the frequency of the coexpression of gastric
MUC5AC and MUC6 in the immunohistochemical O-
type was significantly higher than those in the immuno-
histochemical I-type or PB-type. These results provide
evidence that both the immunohistochemical I-type and
immunohistochemical PB-type have low-grade expres-
sion of gastric mucins. Expression of these gastric
MUCs in the immunohistochemical O-type indicates
that both gastric foveolar and pyloric gland metaplasia
occur in the immunohistochemical O-type[19-21]. In
addition, patients with tumors of the immunohisto-
chemical O-type and MUC5AC and MUC6 coexpres-
sion had a significantly longer survival than those with
tumors that did not show this coexpression. Among the
tumors of the immunohistochemical O-type, those nega-
tive for the coexpression were at a more advanced pT
stage than those positive for the coexpression. The prog-
nosis of tumors of the immunohistochemical O-type
that were positive or negative for the coexpression may
depend on the tumor stage. Thus, gastric differentiation
of the immunohistochemical O-type is associated with
good prognosis. Interestingly, our observations of the
histological unusual type were similar.
A B C
Figure 6 Hematoxylin and eosin staining of immunohistochemical other-type tumors (A). Positive expression of MUC5AC antibody (B) and
MUC6 antibody (C) in immunohistochemical other-type tumors (A: ×20; B, C: ×20).
Table 7 Correlation of MUC5AC and MUC6 Coexpression
with Immunohistochemical Classification
I-type PB-type O-type P*
(N = 11)
(%)
(N = 15)
(%)
(N = 17)
(%)
MUA5AC and
MUC6
18 13 53 p =
0.031
* c
2 test.
Table 8 Correlation of Tumor Parameters and MUC5AC
and MUC6 Coexpression with Immunohistochemical
O-type
O-type(No. of cases)
MUC5AC +/MUC6 + MUC5AC -/MUC6 -
(N = 9) (N = 8)
T-stage
I3 1
II 5 3
III 1 4
IV 0 0
Nodal metastasis
Negative 5 3
Positive 4 5
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MUC1, MUC2, MUC5AC, and MUC6 in ACs. On the
basis of the histological classification of ACs, we found
that CK20 had a high sensitivity for the histological
intestinal type and MUC1 had high sensitivity for the
histological pancreatobiliary type carcinoma. On the
basis of the observed differences in the expression pat-
terns of both CK and MUC, we defined immunohisto-
chemical subtypes. These immunohistochemical
subtypes correlated well with the conventional histo-
morphological classification but did not correlate with
prognosis. However, the coexpression of gastric
MUC5AC and MUC6 correlates with the prognosis of
patients with the immunohistochemical O-type of AC.
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